STAT Summit

At the 2019 STAT Summit, Matthew Herper, senior medicine writer and editorial director of events, and the rest of the STAT team assembled top executives and researchers, policymakers, and patient advocates to scout the future of medicine — the biggest advances and the emerging challenges — and identify ways to push the limits of what’s possible for human health.

See our list of stories from the 2019 STAT Summit below.

All Coverage

Biotech By Nicholas Florko

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Politics By Nicholas Florko

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

Politics By Nicholas Florko

As FDA toils over how to regulate CBD, frustration builds on all sides

Pharmalot By Ed Silverman

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

STAT Summit By Casey Ross

A bold prediction: Machine learning will yield new drug candidates within three years

Biotech By Kate Sheridan

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

In the Lab By Rebecca Robbins

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Health By Shraddha Chakradhar

Most Read

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?

Watch: Top FDA official talks bringing the agency into a new age

A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award

Watch: The state of biotech at time of innovation — and high prices

STAT Summit: The hypebusters who spoke truth to power